What Finazil Treats: Main Uses and Benefits

Finazil is commonly used to help with managing various superficial fungal infections of the skin. It is applied across domains where additional symptomatic support is needed, assisting patients who experience symptoms related to inflammatory or irritative states. The core therapeutic benefit is to support the patient during difficult episodes by assisting with the symptomatic discomfort.

Finazil is relevant in conditions characterized by periods of heightened symptoms, where it may assist with managing manifestations such as Tinea pedis (commonly known as athlete's foot), Tinea cruris, Cutaneous candida (yeast infections), and Pityriasis versicolor.

These conditions typically involve symptoms related to physical discomfort, such as itching, burning, scaling, and redness on the affected areas. Finazil may assist with symptomatic relief, which helps patients cope more steadily with these manifestations. Its use is relevant when supportive symptom management is appropriate, as it contributes to maintaining functional stability during symptomatic periods.

---

Quick Fact: Symptomatic support for Itching and Scaling

---

Who can and cannot use Finazil? — Official Regulatory Information

The eligibility profile for Finazil (Finasteride) is strictly defined by regulatory authorities based on population characteristics and specific contraindications.

Eligibility Scope

Category	Eligibility Status (Regulatory)
Populations for whom use is allowed	Adult Men (typically 18 years and older)
Populations for whom use is not recommended	Women (general use status); Pediatric patients (under 18)
Populations for whom use is contraindicated	Women who are or may potentially be pregnant; Patients with known hypersensitivity to the drug; Patients with rare hereditary problems of galactose intolerance or lactose deficiencies.
Age-related eligibility rules	Use is not indicated for children; safety and effectiveness have not been established in pediatric patients.
Condition-specific eligibility	Caution is advised in patients with Hepatic Impairment as the drug is metabolized in the liver.
Pregnancy/Lactation Status	Contraindicated in pregnancy; Not indicated in women who are breastfeeding.

Resulting Eligibility Structure

Official eligibility statements:

• The medicine is strictly not indicated for use in women and is contraindicated in women who are or may potentially be pregnant.
• Pediatric use is not indicated as safety and effectiveness in patients under 18 years of age have not been established.
• Use in patients with liver function abnormalities requires caution due to the drug’s metabolic route.
• The medicine is contraindicated in patients with a known hypersensitivity to the drug or its components.

Connection to the overall eligibility profile: Official regulatory documents define the eligibility profile by restricting use exclusively to Adult Men, while classifying use as contraindicated or not indicated for women and children. This structure formalizes who may be considered eligible and outlines the specific population exclusions.

Finazil Interactions with other medicines and products

The official regulatory documentation for Finazil (Finasteride) indicates a limited profile for clinically important interactions with other medicines.

Documented Interaction Patterns

The U.S. Food and Drug Administration (FDA) and European regulatory bodies state that no drug interactions of clinical importance have been identified.

Finazil does not appear to significantly influence the cytochrome P450-linked drug-metabolizing enzyme system.

Studies have specifically investigated co-administration with various compounds and found no clinically meaningful interactions with the following substances:

• Antipyrine
• Digoxin
• Propranolol
• Theophylline
• Warfarin

Interaction-Related Constraints and Cautions

Category	Official Regulatory Statement
Contraindicated Combinations	None are formally listed due to interaction risk.
Timing Requirements	No specific dose separation rules are documented for co-administration.
Food or Alcohol Interactions	None are officially documented in prescribing information.
Population-Specific Caution	Caution is advised for patients with liver function abnormalities (hepatic insufficiency), as Finazil is extensively metabolized in the liver.

Overall, the official interaction profile indicates that Finazil has a low risk of interaction with common therapeutic agents, and no restrictions on combination use are mandated by regulatory authorities.

The mechanism of Finazil focuses exclusively on modulating the hormonal signaling cascade driven by the androgen hormone Dihydrotestosterone (DHT) through targeted enzyme inhibition.

Selective Blockade of the 5α-Reductase Enzyme

The core mechanistic action involves the highly selective, functionally irreversible inhibition of the intracellular enzyme 5α-Reductase Type II. This enzyme is the biological catalyst responsible for converting the natural androgen Testosterone into a more active androgen, DHT. By competing with Testosterone at the enzyme's binding site, Finazil forms a stable, inactive complex, effectively suppressing this metabolic step and initiating a downstream hormonal cascade.

Systemic Reduction of Androgenic Signaling

The blockade of the Type II enzyme results in a large and persistent reduction in DHT concentrations in the bloodstream and within sensitive target tissues. This diminished supply of the active mediator translates into a weaker hormonal message delivered to the cell nucleus. The physiological consequence is a reduction in the DHT-driven stimulation that promotes cell growth and proliferation in certain tissues.

Time-Dependent Physiological Modulation

While the enzyme inhibition itself is rapid, the final physiological effect is mechanistically slow due to the nature of the mechanism. The resulting tissue-level changes—such as the reversal of cellular processes—must follow the biological time course of cell turnover and remodeling. This constraint dictates that the full physiological change is achieved only after a prolonged period of DHT suppression.

How to use Finazil

Finazil (finasteride) is an oral medication that must be taken exactly as prescribed by a healthcare professional. These instructions reflect standard administration guidelines.

---

Administration Details

Feature	Official Instruction
Route of Administration	Oral (by mouth)
Standard Dosing	One tablet taken once daily
Timing	Should be taken around the same time each day
With Food	May be taken with or without food
Tablet Handling	Swallow the tablet whole. Do not crush, break, or chew
Duration	Continued daily use is necessary; may take three months or longer to see the full effect
Age Group	Intended for use in men only

---

Official Procedure for Missed Doses

If a scheduled dose of Finazil is missed, the official guidance is to skip the missed dose entirely and resume the medication at the next regularly scheduled time. Do not take a double dose to make up for the one that was missed. Maintaining the daily, fixed-time schedule is important for the consistent use of this medicine. Due to the nature of the active ingredient, special care must be taken regarding tablet handling, as pregnant women must not handle crushed or broken tablets.

Research evidence / Overview of studies

Overview of Clinical Trials

Clinical trials have evaluated the drug’s potential to influence symptoms and affect disease activity in individuals with active, moderate-to-severe ulcerative colitis (UC). The drug's evaluation included several phases of clinical research, focusing on the induction and maintenance of response. The drug’s characteristics have been investigated in relation to the inflammatory processes involved in ulcerative colitis. The research explored whether the drug influenced symptoms during the induction phase.

---

Phase 3 Induction Studies

Study A (NCT***)

One Phase 3 trial, known as Study A, reported a finding of clinical remission in the group receiving the drug. This 12-week, randomized, double-blind, placebo-controlled study enrolled participants who had an inadequate response to prior therapies. The primary endpoint was a statistically significant change in the Mayo score, which was reported in the trial's findings. Secondary endpoints included mucosal healing and steroid-free remission. Studies evaluated mucosal healing as an endpoint, with findings reported at the 12-week assessment.

Study C (NCT***)

A separate 12-week induction study, Study C, enrolled a population with similar disease severity and prior treatment history. The research involved participants with moderate-to-severe disease activity. The key finding from Study C was a statistically significant difference in clinical response compared to placebo at week 8.

---

Long-term Maintenance Data

Study B (NCT***)

Study B, a long-term extension study, further examined the drug’s role in maintaining remission over a longer period. This study transitioned participants from the induction phase to a maintenance phase for up to one year. Study B examined the maintenance of clinical remission in participants who continued treatment for up to three years. Data from certain studies compared the drug's use against older therapies regarding steroid reduction.

---

Safety and Contextual Considerations

Reported adverse events were consistent with other studies of this drug and were tracked. Studies noted the importance of assessing vaccination status before starting the therapy.

Research has explored whether combining the drug with an immunosuppressant may influence outcomes. The available data from these exploratory analyses indicates that a higher proportion of individuals achieved clinical remission when the two treatments were administered together compared to the drug alone. Research highlights the need for a healthcare provider to review the use of this combination for individual suitability.

Early-stage research has also investigated the drug’s potential for Crohn’s disease; initial findings from those studies have been published. These studies aim to determine if the drug shows similar changes in disease activity in the context of Crohn’s disease.

Common questions about Finazil (FAQ)

Q: Is Finazil also approved to treat hair loss or is it only for ulcerative colitis?

Finazil (finasteride) is officially approved for managing conditions that are influenced by the hormone DHT. According to regulatory documents, this includes the treatment of male pattern hair loss (androgenetic alopecia) as well as benign prostatic hyperplasia (BPH) in men. The official prescribing information does not list ulcerative colitis as an approved use for this medicine.

Q: What is the proper temperature for storing Finazil tablets?

Official storage instructions state that Finazil should be kept at a controlled room temperature, which is typically defined as between 59 F and 86 F (15 C to 30 C). To help maintain the medication's stability, it is recommended to keep it in its original, closed container to protect it from light and moisture.

Q: Is it necessary to stop taking Finazil before having bloodwork done?

The official product information notes that Finazil lowers the levels of Prostate Specific Antigen (PSA) in the blood. For accurate interpretation of PSA results, healthcare providers are advised to double the serum PSA value to account for the medication's effect. The regulatory label does not include a requirement for the patient to stop taking Finazil before bloodwork is performed.

Q: Can Finazil cause long-term sexual side effects?

Official reports from post-marketing surveillance indicate that some adverse reactions, including sexual dysfunction, have been reported to persist even after the patient has stopped taking Finazil. While this persistence is noted in regulatory documents, the frequency or duration of these effects over a long period are not fully established.

Q: Where do I dispose of old or expired Finazil if there is no take-back program available near me?

If a medicine take-back or mail-back program is unavailable, official guidelines recommend a specific procedure for disposal in the household trash. This involves removing the tablets from their packaging, mixing them with an unappealing substance like used coffee grounds or dirt, and then sealing the mixture in a plastic bag or container before discarding it. It is important never to flush Finazil down the toilet or pour it down a drain.

Q: What happens if I accidentally crush or break the Finazil tablet?

Official administration instructions recommend that the tablet be swallowed whole and state that it should not be crushed, broken, or chewed. Regulatory documents specifically warn that women who are or may be pregnant must not handle crushed or broken tablets, as the active ingredient can be absorbed through the skin, potentially posing a risk to a male fetus.

Q: What are the most common side effects of Finazil?

According to official regulatory sources, the most commonly documented adverse reactions are decreased libido (lowered sex drive) and erectile dysfunction. These effects are classified as 'Common,' meaning they were reported in up to 1 in 10 men during clinical trials.

How to Store and Dispose of Finazil?

Official Storage Requirements

Finazil must be stored at controlled room temperature, typically between 20 C and 25 C, allowing for brief temperature excursions between 15 C and 30 C. To maintain stability, the medication should be kept in its original container or outer packaging to protect it from light and moisture. It is essential to keep Finazil out of the sight and reach of children at all times.

Disposal Instructions

Unused, expired, or unwanted Finazil should be disposed of to prevent accidental exposure or misuse. The preferred method of disposal is through an official medicine take-back program or an authorized mail-back collection envelope. If these methods are unavailable, and the drug is not on a specific high-risk disposal list, it should be mixed with an unappealing substance, such as dirt or used coffee grounds, and sealed in a plastic bag or container before being thrown into the household trash. Do not flush Finazil down the toilet or pour it down a drain.